自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察

doi:10.11904/j.issn.1002-3070.2015.04.011

实用肿瘤学杂志 ›› 2015, Vol. 29 ›› Issue (4): 342-346.doi: 10.11904/j.issn.1002-3070.2015.04.011

自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察

张丽坤,曹峰林

哈尔滨医科大学附属第一医院血液肿瘤研究所(哈尔滨 150001)

收稿日期:2015-04-07 出版日期:2015-08-27 发布日期:2015-08-27
通讯作者: 曹峰林 E-mail:1982zhanglikun@gmail.com
作者简介:张丽坤,女,(1982-),硕士,技师,从事CIK细胞培养及临床应用的研究
基金资助:
新型免疫细胞治疗产品的研发和规模化制备(2012AA020903)

Effect of autologous cytokine induced killer cell therapy in patients with lung cancer

ZHANG Likun,CAO Fenglin

Institute of Hematology and Oncology,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Received:2015-04-07 Online:2015-08-27 Published:2015-08-27

摘要/Abstract

摘要： 目的评估CIK细胞(Cytokine-induced killer cell,CIK)治疗晚期肺癌的临床疗效。方法从32例晚期肺癌患者外周血中分离出单个核细胞(PBMC),加入含有IFN-γ、IL-2和抗CD3单抗等细胞因子的培养基进行培养,培养15天后分次回输给患者。观察患者治疗前后瘤体变化、免疫指标变化、临床症状的改善情况和毒副反应,进行临床疗效评价。结果 32例接受CIK治疗的患者临床症状明显改善,毒副反应轻。免疫表型分析结果显示CD3/CD4共表达34.4%,CD3/CD8共表达68.2%,CD3/CD56共表达13.7%。CIK细胞回输后约15天CT影像显示胸腔积液减少。临床疗效评价有效率为56.0%,疾病控制率(CR+PR+SD)为84.3%。结论 CIK细胞免疫疗法可以改善肺癌患者免疫功能,抑制肿瘤生长,改善临床症状,改善生存质量。

关键词: CIK细胞, 肺癌, 细胞免疫

Abstract: Objective To evaluate the clinical effect of cytokine induced killer cellular immunotherapies(CIK)on the patients with advanced lung cancer.Methods Peripheral blood mononuclear cell from 32 cases of patients with advanced lung cancer were isolated.Cells were cultured in DMEM supplemented with IFN-γ,IL-2,anti-CD3 monoclonal antibody and other cytokines,and transfused back into the patients in several times after 15 days of culture.Subsequently,we observed the size of tumor,the change of immunologic function by CIK treatment,the status of clinical symptoms,and the toxic and side effect.The clinical curative effect was also evaluated.Results The symptoms in 32 patients who received CIK therapy were reduced,and the side effects were light.Immunophenotype analysis showed that CD3 / CD4 coexpression were found in 34.4% patients,CD3 / CD8 coexpression in 68.2%,and CD3 / CD56 co-expression in 13.7% patients.CT images about 15 days after CIK cell transfusion showed that pleural effusion were decreased.Clinical evaluation effective rate was 56.0%,and disease control rate(CR + PR + SD)was 84.3%.Conclusion CIK cell immunotherapies of cancer patients can improve immunologic function of cancer patients and inhibit tumor growth and relieve the clinical symptom of patients,and improve the quality of life.

Key words: CIK cells, Lung cancer, Cellular immune

中图分类号:

张丽坤,曹峰林. 自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察[J]. 实用肿瘤学杂志, 2015, 29(4): 342-346.

ZHANG Likun,CAO Fenglin. Effect of autologous cytokine induced killer cell therapy in patients with lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 342-346.

参考文献

1 Walker S.Updates in non-small cell lung cancer[J].Clin J Oncol Nurs,2008,12(4):587-596.
2 Spira A,Ettinger DS.Multidisciplinary management of lung cancer[J].N Engl J Med,2004,350(4):379-392.
3 Patel S,Mehta-Damani A,Shu H,et al.An analysis of variability in the manufacturing of dexosomes:implications for development of an autologous therapy[J].Biotechnol Bioeng,2005,92(4):238-249.
4 Shi M,Zhang B,Tang ZR,et al.Autologous cytokine induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma[J].World J Gastroenterol,2004,10(4):1146-1151.
5 Zhang YS,Yuan FJ,Jia GF,et al.CIK cells from patientswith HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R[J].World J Gastroenterol,2005,22(11):3339-3345.
6 Kim HM,Lim J,Park SK,et al.Antitumor activity of cytokine-induced killer cells against human lung cancer[J].Int Immunopharmacol.2007,7(13):1802-1807.
7 Niu Q,Wang W,Li Y,et al.Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies[J].Int Immunopharmacol,2011,11(4):449-456.
8 Schmidt-Wolf IG,Lefterova P,Mehta BA,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,13(21):1673-1679.
9 Helms MW,Prescher JA,Cao YA,et al.IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy[J].Cancer Immunol Immunother,2010,59(9):1325-1334.
10 Yang Z,Zhang Q,Xu K,et al.Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model[J].PLoS One,2012,7:e44802.
11 Schmidt-Wolf IG,Lefterova P,Johnston V,et al.Propagation of large numbers of T cells with natural killer cell markers[J].Br J Haematol,1994,87(3):453-458.
12 Linn YC,Lau LC,Hui KM.Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts[J].Br J Haematol,2002,116(1):78-1186.
13 Linn YC,Hui KM.Cytokine-induced killer cells:NK-like T cells with cytotolytic specificity against leukemia[J].Leuk Lymphoma,2003,44(9):1457-1462.
14 Wu C,Jiang J,Shi L,et al.Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced nonsmall cell lung cancer[J].Anticancer Res,2008,28(6B):3997-4002.
15 Liu L,Zhang W,Qi X,et al.Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J].Clin Cancer Res,2012,18(6):1751-1759.
16 吕俊杰,陶秀娟.CIK治疗恶性肿瘤的基础与临床研究[J].实用肿瘤学杂志,2012,26(4):373-376.

[1]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[2]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[3]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[4]	张彦秋,韩阿蒙,李金旺,顾涛,付占昭,毛羽,张子健,杨振. CRT+ARC技术在局部晚期肺癌患者中临床应用的初步研究[J]. 实用肿瘤学杂志, 2019, 33(3): 256-260.
[5]	赵苏, 郑晓瑜, 朱开彬, 卜建龙, 徐世东. 肺癌完全性切除术对患者外周血中Th17/Treg细胞平衡的影响[J]. 实用肿瘤学杂志, 2019, 33(2): 142-148.
[6]	胡智慧综述, 张静审校. SNP对放射性肺损伤预测作用的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 87-91.
[7]	迪娜·木拉力, 胡昕综述, 加孜那·托哈依审校. 远程医疗在肺癌中的应用及前景[J]. 实用肿瘤学杂志, 2018, 32(6): 555-557.
[8]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[9]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[10]	钟雪莱, 杨海粒, 王国年. 不同麻醉方式对老年肺癌患者术后认知功能的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 432-436.
[11]	朱晓云, 张亚宁, 林菲, 马碧萍. 上海市金山区2002-2013年肺癌发病及死亡分析[J]. 实用肿瘤学杂志, 2018, 32(5): 437-441.
[12]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[13]	魏静, 陶媛美慧, 付英梅, 赵吉子, 张文莉, 张凤民. 肺结核与肺癌相互影响的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 340-343.
[14]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[15]	万静萱, 李红红, 周湘乡, 马琳. Ⅳ期肺癌合并肺血栓栓塞的危险因素分析[J]. 实用肿瘤学杂志, 2018, 32(3): 214-244.

自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察

Effect of autologous cytokine induced killer cell therapy in patients with lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价